CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been reported to engage in a transaction involving the company's stock. The action took place on October 16, 2024. However, the announcement did not disclose the type of action, its status, the number of shares involved, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Bruno after the transaction was not provided. This leaves a gap in information for investors who might be monitoring insider activity as an indicator of the company's health and potential future performance.

CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been reported to engage in a transaction involving the company's stock. The action took place on October 16, 2024. However, the announcement did not disclose the type of action, its status, the number of shares involved, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Bruno after the transaction was not provided. This leaves a gap in information for investors who might be monitoring insider activity as an indicator of the company's health and potential future performance.